ARTICLE | Financial News
Following JV, Sino backs Akeso's $150M series D
November 5, 2019 12:58 AM UTC
Six months after establishing a joint venture with Akeso, Sino Biopharmaceutical has co-led a series D round of about $150 million in the Zhongshan-based cancer and autoimmune company.
Loyal Valley Capital co-led the round, which saw participation from Shenzhen Capital, Lake Bleu Healthcare Fund, China Reform Conson Soochow Overseas Fund I LP, AIHC, OrbiMed, K. Wah Group, CCB Capital, Apricot Capital, Triwise Capital and BOCOM International...
BCIQ Company Profiles